46951
フルオロセインイソチオシアナート, アイソマー I
≥97.5% (HPLC)
別名:
FITC, フルオレセイン 5-イソチオシアナート
ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
実験式（ヒル表記法）:
C21H11NO5S
CAS番号:
分子量:
389.38
EC Number:
222-042-0
UNSPSC Code:
12171500
PubChem Substance ID:
Beilstein/REAXYS Number:
1407295
MDL number:
Quality Level
assay
≥97.5% (HPLC)
form
powder
impurities
≤1.5% Isomer II
mp
>360 °C (lit.)
solubility
acetone: soluble 0.1 g/10 mL
fluorescence
λex 492 nm; λem 518 nm (green), λex 492 nm; λem 518 nm in 0.1 M phosphate pH 8.0
storage temp.
2-8°C
SMILES string
Oc1ccc2c(Oc3cc(O)ccc3C24OC(=O)c5cc(ccc45)N=C=S)c1
InChI
1S/C21H11NO5S/c23-12-2-5-16-18(8-12)26-19-9-13(24)3-6-17(19)21(16)15-4-1-11(22-10-28)7-14(15)20(25)27-21/h1-9,23-24H
InChI key
MHMNJMPURVTYEJ-UHFFFAOYSA-N
Application
タンパク質のFITC標識試薬; タンパク質とペプチドのマイクロシ-クエンス(HPLC)
Still not finding the right product?
Explore all of our products under フルオロセインイソチオシアナート, アイソマー I
signalword
Danger
Hazard Classifications
Resp. Sens. 1 - Skin Sens. 1
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
hcodes
Aram Ghalali et al.
Carcinogenesis, 35(7), 1547-1555 (2014-01-24)
Epidemiological studies indicate that statins, cholesterol-lowering drugs, prevent aggressive prostate cancer and other types of cancer. Employing essentially non-prostate cell lines, we previously showed that statins rapidly downregulate nuclear levels of phosphorylated Akt via P2X7, a purinergic receptor recently implicated
T Matthes et al.
Leukemia, 29(9), 1901-1908 (2015-03-11)
Multiple myeloma (MM) is a non-curable tumor developing in the bone marrow (BM). The BM microenvironment rich in hematopoietic precursors is suspected to have a role in MM development. Here we show that a proliferation-inducing ligand (APRIL) mediated in vivo
Eddie A James et al.
Arthritis & rheumatology (Hoboken, N.J.), 66(7), 1712-1722 (2014-03-26)
Rheumatoid arthritis (RA) is thought to be a T cell-mediated disease, based on its strong association with HLA class II alleles, clinical responsiveness to T cell-directed therapies, and the presence of CD4+ T cells in rheumatoid joints. The presence of